Search Results

12-Month DANCE Pilot Study Results Presented

October 10, 2013—Christopher Owens, MD, presented the 12-month results of the DANCE pilot study at the VIVA 2013: Vascular Interventional Advances conference on October 8–11 in Las Vegas, Nevada.

Early Findings Presented for PQ Bypass' Endovascular Femoropopliteal Artery Bypass Procedure

September 14, 2016—PQ Bypass, Inc., which is developing a fully percutaneous approach (the PQ Detour procedure) to femoropopliteal bypass surgery, announced that early results of a study using the PQ bypass system were presented by Piotr Szopiński, MD, at CIRSE 2016, the annual meeting of the Cardiovascular and Interventional Radiology Society of Europe annual meeting in Barcelona, Spain.

Proteon Therapeutics' Vonapanitase Evaluated in Symptomatic PAD Patients

October 12, 2015—Proteon Therapeutics, Inc. announced that results from its phase 1 study of investigational vonapanitase in patients with symptomatic peripheral artery disease (PAD) were presented at TCT 2015, the 27th annual Transcatheter Cardiovascular Therapeutics scientific symposium of the Cardiovascular Research Foundation being held October 11-15 in San Francisco, California.

Proteon Therapeutics Studies Investigational Vonapanitase to Treat Symptomatic PAD

August 21, 2015—Proteon Therapeutics Inc. recently announced top-line results from its phase 1 study of investigational vonapanitase in patients with symptomatic peripheral artery disease (PAD).

R3 Vascular Receives IDE Approval for ELITE-BTK Pivotal Trial of Magnitude Scaffold

November 13, 2024—R3 Vascular Inc. recently announced that the FDA granted investigational device exemption (IDE) approval to initiate the company’s ELITE-BTK pivotal trial of Magnitude, its next-generation drug-eluting bioresorbable scaffold for treating below-the-knee (BTK) peripheral arterial disease (PAD) with the potential of addressing chronic limb-threatening ischemia.

Efemoral Medical Awarded Phase II SBIR Grant From NIH for Vascular Scaffold System

September 22, 2022—Efemoral Medical, developer of interventional bioresorbable therapies, announced that it has been awarded a phase II Small Business Innovation Research (SBIR) grant, which is supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health (NIH).

Efemoral Medical’s EVSS Device Development Supported by New Funding

December 13, 2022—Efemoral Medical, a developer of next-generation bioresorbable solutions to treat patients with vascular disease, announced the closing of its $4.9M preferred Series A1 round.